Expansion of Maternity Services Ascension Saint Thomas Rutherford and Ascension Saint Thomas Hospital Midtown have been ...

With the growing number of high-risk pregnant women, echocardiography frequently reveals pericardial effusion (PE). However, the clinical implications of PE are unknown.We analyzed a cohort of 406 ...

Edward Lifesciences remains a "Hold" as it trades close to its intrinsic value, despite improved fundamentals and solid third ...

The global endoprosthesis market is on the cusp of substantial growth, with projections indicating a surge from USD 26.196 Million in 2022 to an estimated USD 74,381.47 Million by 2032, reflecting a ...

Dr V V Smith, Histopathology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, UK. Three infants, who presented with intestinal obstruction due to ...

Emergency and Critical Care Medicine 2024年第4期创伤专题正式上线, 本期由1篇Perspective/Viewpoint，3篇Original article，2篇Review，1篇Communication ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

Over the past 10 years, we have fine-tuned the ability to replace valves without open-heart surgery. As of this writing, ...

Nitinol had a big year in 2024, from major supply chain deals to big advances in the development and use of groundbreaking ...

Kolaleh Eskandanian, chief innovation officer at Children’s National Hospital, said the partnership is meant to address the many challenges with developing devices for children and infants.

Edwards Lifesciences Co. (NYSE:EW – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $72.91 and traded as high as $75.35.